BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research

Rhea-AI Summary

PreveCeutical Medical (OTCQB: PRVCF) has announced the appointment of Dr. Kamal Albarazanji as Senior Director of Metabolic Research at its subsidiary BioGene Therapeutics, effective August 18, 2025. Dr. Albarazanji brings extensive experience in metabolic research, having previously served as a Senior Scientist in Cardiovascular & Metabolic Diseases.

Dr. Albarazanji's background includes significant work at SmithKline Beecham (now GSK) on various therapeutic programs, including renin inhibitors and insulin sensitizers. He holds multiple patents and has authored over 20 peer-reviewed publications in prestigious journals. His expertise spans in vivo pharmacology, target validation, and translational research, with particular focus on metabolic diseases, obesity, and diabetes treatments.

Positive

• Appointment of highly experienced scientist with expertise in metabolic research and drug development
• Addition of proven leadership in advancing compounds from discovery to clinical trials
• Strong track record with 20+ peer-reviewed publications and multiple patents

Negative

• None.

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Kamal Albarazanji as Senior Director of Metabolic Research effective on 18 August, 2025.

Dr. Albarazanji brings a wealth of expertise in in vivo pharmacology, target validation, and translational research. Most recently, he served as a Senior Scientist in Cardiovascular & Metabolic Diseases at a leading pharmaceutical company, where he led programs on enteropeptidase inhibitors for metabolic diseases and AMPK activators for acute kidney injury. His career spans notable roles at SmithKline Beecham (now GSK), where he contributed to groundbreaking work on renin inhibitors for hypertension, insulin sensitizers like Avandia, and neuropeptide programs for obesity. Dr. Albarazanji has championed multiple novel targets, including GPR39 agonists, muscarinic M3 receptor antagonists, and vasopressin V1b antagonists, resulting in significant advancements in weight loss, glucose metabolism, and gastrointestinal hormone regulation.

A prolific researcher, Dr. Albarazanji holds numerous patents and has authored over 20 peer-reviewed manuscripts in prestigious journals such as Diabetes, Journal of Pharmacology and Experimental Therapeutics, and American Journal of Physiology. His work has been presented at major conferences, including the American Diabetes Association and Keystone Symposia, and he has been instrumental in advancing compounds from discovery to clinical trials.

"We are thrilled to welcome Dr. Albarazanji to BioGene Therapeutics," said Stephen Van Deventer, Chairman & CEO of BioGene Therapeutics Inc. "His deep knowledge in metabolic disease biology and proven track record in leading cross-functional teams will accelerate our pipeline of innovative therapeutics. Kamal's vision aligns perfectly with our mission to address unmet needs in obesity and diabetes through cutting-edge science."

"I am excited to join BioGene Therapeutics at this pivotal time," said Dr. Albarazanji. "The company's commitment to leveraging novel mechanisms for metabolic health resonates with my passion for translating research into life-changing treatments. I look forward to collaborating with the talented team to advance our programs and deliver meaningful outcomes for patients."

Dr. Albarazanji earned his Ph.D. in Physiology from the University of Manchester and began his career with foundational research on neuroendocrine regulation. His appointment is effective immediately.

About PreveCeutical Medical Inc.

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

About BioGene Therapeutics Inc.

BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5% R&D tax cashback incentive. This subsidiary supports ongoing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research advancing gene therapy-based approaches designed to address the growing global diabetes and obesity crisis. For more information about BioGene, please visit our website https://biogenetherapeutics.com.

On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer

For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com

Forward-Looking Statements:

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263042

FAQ

Who is Dr. Kamal Albarazanji and what is his new role at PRVCF?

Dr. Kamal Albarazanji is the newly appointed Senior Director of Metabolic Research at BioGene Therapeutics, a subsidiary of PreveCeutical Medical, effective August 18, 2025. He previously served as a Senior Scientist in Cardiovascular & Metabolic Diseases.

What is Dr. Albarazanji's experience in pharmaceutical research?

Dr. Albarazanji has extensive experience at SmithKline Beecham (now GSK), where he worked on renin inhibitors, insulin sensitizers, and neuropeptide programs. He has authored over 20 peer-reviewed publications and holds multiple patents.

How will Dr. Albarazanji's appointment impact PreveCeutical's research direction?

Dr. Albarazanji will accelerate BioGene Therapeutics' pipeline of innovative therapeutics, focusing on addressing unmet needs in obesity and diabetes through his expertise in metabolic disease biology and cross-functional team leadership.

What are Dr. Albarazanji's key research achievements?

Dr. Albarazanji has led programs on enteropeptidase inhibitors for metabolic diseases, AMPK activators for acute kidney injury, and has championed novel targets including GPR39 agonists and muscarinic M3 receptor antagonists for weight loss and glucose metabolism.